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ABSTRACT
Objective Sex differences in risk factors of aortic valve 
calcification (AVC) by echocardiography have not been 
reported from a large prospective study in aortic stenosis 
(AS).
Methods AVC was assessed using a prognostically 
validated visual score and grouped into none/mild or 
moderate/severe AVC in 1725 men and women with 
asymptomatic AS in the Simvastatin Ezetimibe in Aortic 
Stenosis study. The severity of AS was assessed by the 
energy loss index (ELI) taking pressure recovery in the 
aortic root into account.
Results More men than women had moderate/severe 
AVC at baseline despite less severe AS by ELI (p<0.01). 
Moderate/severe AVC at baseline was independently 
associated with lower aortic compliance and more severe 
AS in both sexes, and with increased high-sensitive 
C reactive protein (hs-CRP) only in men (all p<0.01). 
In Cox regression analyses, moderate/severe AVC at 
baseline was associated with a 2.5-fold (95% CI 1.64 to 
3.80) higher hazard rate of major cardiovascular events 
in women, and a 2.2-fold higher hazard rate in men 
(95% CI 1.54 to 3.17) (both p<0.001), after adjustment 
for age, hypertension, study treatment, aortic compliance, 
left ventricular (LV) mass and systolic function, AS 
severity and hs-CRP. Moderate/severe AVC at baseline 
also predicted a 1.8-fold higher hazard rate of all-
cause mortality in men (95% CI 1.04 to 3.06, p<0.05) 
independent of age, AS severity, LV mass and aortic 
compliance, but not in women.
Conclusion In conclusion, AVC scored by 
echocardiography has sex-specific characteristics in 
AS. Moderate/severe AVC is associated with higher 
cardiovascular morbidity in both sexes, and with higher 
all-cause mortality in men.
Trial registration number  ClinicalTrials. gov identifier: 
NCT00092677
INTRODUCTION
Sex differences in aortic stenosis (AS) have been 
pointed out both at the valvular and left ventric-
ular (LV) level.1 From the large Simvastatin Ezeti-
mibe in Aortic Stenosis (SEAS) study, sex differ-
ences in LV adaptation during progression of AS 
were recently reported, despite similar rate of AS 
progression in both sexes.2 By multidetector CT, it 
was demonstrated by Aggarwal et al that women 
have significantly lower aortic valve calcification 
(AVC) load than men independent of the severity of 
AS.3 From this, sex-specific cut-off values for Agat-
ston score indicating severe AS were developed and 
validated.3 4 Although cardiac CT more accurately 
measures AVC in AS and may help identify severe 
AS in asymptomatic patients with discordantly 
graded AS by conventional echocardiographic 
measures, it is not recommended by current guide-
lines as a routine test in patients with AS.5 While 
CT primarily quantifies areas of valvular macro-
calcification, recent studies by positron emission 
tomography have revealed that AVC also includes 
inflammation and microcalcification.6 7 Since 
different processes involved in AVC are reflected 
by echocardiography and CT, AVC by echocardi-
ography is not synonymous with AVC assessed by 
CT.8 The association of AVC scored by echocar-
diography with higher rates of combined aortic 
valve replacement and death has previously been 
documented in two studies by Rosenhek et al.9 10 
However, sex-specific risk factors and prognostic 
implications of AVC scored by echocardiography 
have not been published from a large, prospective 
study. This was the aim of the present study.
METHODS
Study population
The present analysis of the SEAS study included 
the 1725 men and women (92% of the total study 
population) that had images available for AVC 
scoring on the baseline echocardiogram. Compared 
with ineligible patients, the patients selected for the 
present analysis did not differ in age, sex, preva-
lence of hypertension or severity of AS (all p<0.05). 
The SEAS study protocol, baseline characteristics 
and outcome have been previously published.11 12 
In short, 1873 asymptomatic patients with mostly 
moderate AS and without known diabetes, cardio-
vascular or renal disease were randomised to 
double-blind, placebo-controlled treatment with 
combined ezetimibe 10 mg and simvastatin 40 mg 
daily for ≥4 years.12 Hypertension was defined as 
history of hypertension, use of antihypertensive 
drug treatment or blood pressure ≥140/90 mm Hg 
at the clinic baseline visit.
Echocardiographic measurements
Echocardiography was performed using a stan-
dardised protocol in 173 study centres in seven 
European countries.13 14 All echocardiograms were 
analysed at the echocardiographic core laboratory 
at Haukeland University Hospital, Bergen, Norway, 
and 94% were proofread by the same experienced 
reader. Quantitative echocardiography for assess-
ment of AS and LV structure and function was 
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performed following current guidelines.5 15 16 Previous analyses 
from the SEAS trial have shown excellent reproducibility for 
measurements of LV dimensions.17 Aortic valve area adjusted for 
pressure recovery in the aortic root (energy loss index (ELI)) was 
used as the primary measure of AS severity, given the superior 
prognostic value previously demonstrated.18 Aortic and mitral 
regurgitation were graded by colour Doppler. AVC was graded 
as none (no calcification), mild (isolated small spots), moderate 
(multiple bigger spots) and severe (extensive calcification of 
all cusps).9 LV mass was calculated using an autopsy validated 
formula.19 LV hypertrophy was considered present if LV mass/
height2.7 was ≥49.2 g/m2.7 in men and 46.7 g/m2.7 in women.20 
LV systolic function was assessed by biplane Simpson’s ejection 
fraction and by midwall shortening adjusted for circumferential 
end-systolic stress taking the mean transaortic valve gradient 
into account (stress-corrected midwall shortening (scMWS)).21 22 
Aortic compliance was assessed from LV stroke volume/pulse 
pressure ratio.23
Study outcomes
The primary outcome of the SEAS study was major cardio-
vascular events, a composite endpoint consisting of aortic 
valve-related events (combined aortic valve replacement, 
congestive heart failure due to AS and cardiovascular death) 
and ischaemic cardiovascular events (combined non-fatal 
myocardial infarction, non-haemorrhagic stroke, coronary 
revascularisation, hospitalisation for unstable angina pectoris 
and cardiovascular death).12 Secondary outcomes included 
aortic valve events and ischaemic cardiovascular events anal-
ysed separately. All-cause mortality was a tertiary endpoint. All 
outcomes were classified by an independent endpoint classifi-
cation committee blinded to study-group assignment.11
Ethics approval
The SEAS study was approved by ethics committees in all partic-
ipating study centres, and all patients provided written informed 
consent.
Statistical analyses
Statistical analyses were performed using IBM SPSS 23.0. 
Patients were grouped according to sex and the baseline severity 
of AVC (none/mild vs moderate/severe AVC). Continuous 
variables are given as mean±SD and categorical variables as 
percentages. Differences between groups were tested by anal-
ysis of variance with Scheffe’s post hoc test and Bonferroni 
adjustment.
The intraclass correlation coefficient was used to assess both 
intraobserver and interobserver variability for the AVC score. 
Intraobserver variability was assessed in 500 randomly selected 
patients scored twice by one experienced sonographer (GC), 
several weeks apart. Interobserver variability was assessed in 150 
randomly selected patients analysed twice by an experienced and 
less experienced reader (DC), respectively. Agreement between 
AVC scores was assessed by the Bland-Altman method using the 
95% limits of agreement and the variation coefficient of the 
mean difference.
 Binary logistic regression analyses reported as OR and 95% 
CIs were used to identify risk factors of AVC in women and 
men. Based on the logistic regression analyses, a propensity 
score for AVC was derived both in women and in men using the 
AVC score as dependent variable and age, aortic compliance, 
ELI, high-sensitive C reactive protein (hs-CRP) and scMWS as 
independent variables. The propensity scores reflect the like-
lihood that an individual patient would develop moderate/
severe AVC versus none/mild AVC given all the other known 
variables other than the outcome variable. The association of 
AVC severity with study outcomes was tested in Kaplan-Meier 
plots with log-rank test and in multivariable Cox regression 
analyses with results reported as HR and 95% CI. We deter-
mined the interaction between gender and AVC by introducing 
the cross product of the two variables in the Cox regression 
analysis for major cardiovascular events. Further on, we run the 
multivariate Cox model separately in women and men and with 
adjustment for age, hypertension, LV mass index, ELI, aortic 
compliance, hs-CRP, scMWS and study treatment allocation. 
The respective covariates were selected based on a stepwise 
backward procedure. Additionally, the propensity scores for 
AVC were forced into the Cox models to account for gender 
differences in the distribution of the respective covariates. We 
examined the validity of the proportionality assumption by 
testing the significance of the covariate–time interaction terms. 
The variables included in the Cox analyses did not violate the 
proportionality assumption.
A p value <0.05 was considered statistical significant in all 
analyses.
Figure 1 Bland-Altman analyses of the aortic valve calcification (AVC) visual score measured by two different readers (A) and twice by the same 
reader (B) with the mean value of the difference between measurements (the solid reference line in each panel) and 95% limits of agreement (the 
dotted lines in each panel).
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RESULTS
Patient demographics
Reproducibility of the AVC visual scoring was excellent with an 
intraobserver agreement of 0.95 and interobserver agreement of 
0.92. There was good interobserver (variation coefficient 4.7%, 
95% limits of agreement −1.05 to 1.24) and intraobserver (vari-
ation coefficient 2.5%, 95% limits of agreement −1.91 to 1.27) 
agreement for scoring of AVC (figure 1). At baseline, moderate/
severe AVC was found in 63% of women and 70% of men 
(p<0.01) (table 1). Irrespective of AVC severity, women were 
older, had higher scMWS and lower LV mass index, aortic valve 
area index and aortic compliance, and included more subjects 
with hypertension compared with men (all p<0.05) (table 1). 
Antihypertensive treatment did not differ between sexes except 
for higher use of diuretics among women in patients with none/
mild AVC (p<0.05). Both men and women with moderate/severe 
AVC at baseline had higher LV mass index and lower scMWS 
compared with their none/mild AVC counterparts (all p<0.05). 
In the same AVC category, AS assessed by ELI was consistently 
more severe in women than in men (figure 2). Among men, 
moderate/severe AVC had higher hs-CRP compared with the 
none/mild AVC group (p<0.05) (table 1).
In logistic regression analyses, moderate/severe AVC was 
associated with lower aortic compliance and more severe AS in 
both sexes (both p<0.01) and with higher serum hs-CRP in men 
(p<0.01) (table 2). In subsequent regression analyses, no asso-
ciation between AVC and serum cholesterol or mitral and aortic 
valve regurgitation were found when they were added to the 
covariates (all p>0.05).
AVC and outcome
In Kaplan-Meier tests, moderate/severe AVC at baseline 
predicted higher rates of major cardiovascular events during a 
median of 4.3 years follow-up in both sexes and higher all-cause 
mortality in men (all p<0.05) (figure 3).
In multivariate Cox analyses, adjusting for differences in base-
line characteristics between groups and known prognosticators 
in AS including age, hypertension, scMWS, LV mass index, 
aortic compliance, ELI, hs-CRP, randomised study treatment 
allocation, as well as the propensity scores for AVC, presence of 
baseline moderate/severe AVC was associated with higher HR of 
combined major cardiovascular events and aortic valve events in 
both sexes (table 3). In further Cox analyses, the results remained 
Table 1 Clinical, biochemical and echocardiographical characteristics of women and men grouped according to aortic valve calcification (AVC) 
severity at baseline
Women (N=664) Men (N=1061)
None/mild AVC(n=247) Moderate/severe AVC(n=417) None/mild AVC(n=322) Moderate/severe AVC(n=739)
Age (years) 68.2±9.4* 69.9±9.3*† 65.3±9.8 66.6±9.5†
Body mass index (kg/m²) 27.5±5.4 26.5±5.1† 27.1±3.6 26.8±3.9
Hypertension 89%‡ 88%‡ 79% 81%
Antihypertensive treatment (%)
Calcium antagonists 36 31 36 32
ACE inhibitors 32 27 35 32
Angiotensin receptor blockers 21 21 19 18
Diuretics 52§ 52 35 46
Beta-blockers 43 42 37 39
No of antihypertensive agents 1.4§ 1.3§ 1.1 1.2
Systolic blood pressure (mm Hg) 150±20‡ 151±21* 145±19 143±19
Diastolic blood pressure (mm Hg) 81±10 82±10 82±10 82±10
Heart rate (beats/min) 69±11* 68±11* 65±12 64±11
Total cholesterol (mmol/L) 6.0±1.0* 6.0±1.1* 5.6±0.9 5.5±1.0
LDL cholesterol (mmol/L) 3.7±0.9 3.7±1.0* 3.6±0.8 3.5±0.9
Creatine (µmol/L) 84±13* 85±14* 98±14 99±15
hs-CRP (mg/dL) 0.26 (0.10–0.49) 0.24 (0.10–0.48) 0.18 (0.08–0.31) 0.20 (0.08–0.44)§
Peak aortic jet velocity (m/s) 2.64±0.34 3.33±0.46† 2.62±0.36 3.32±0.49†
Mean transvalvular gradient 
(mm Hg)
16±4 27±8† 16±5 26±9†
Aortic valve area (cm²) 1.28±0.38* 1.02±0.32*¶ 1.64±0.55 1.27±0.43†
Aortic valve area index (cm²/m²) 0.72±0.21* 0.59±0.19** 0.82±0.28 0.64±0.21†
Energy loss index (cm²/m²) 1.06±0.54 0.77±0.33‡¶ 1.13±0.57 0.83±0.42†
Ejection fraction (%) 67±6 66±7 67±7 66±7†
scMWS (%) 102±19§ 99±20†‡ 98±19 94±19**
LV mass index (g/m2.7) 41.9±12.4‡ 44.2±14.0§* 45.3±15.7 47.9±14.7†
Stroke volume/pulse pressure (mL/
mm Hg)
3.25±1.51* 3.07±1.34* 4.54±2.17 4.21±2.00†
Mitral regurgitation 64% 70%* 55% 54%
Aortic regurgitation 65%‡ 72%‡ 82% 84%
*p<0.001, **p<0.01, †p<0.05 between groups with none/mild versus moderate/severe AVC within same sex, ‡p<0.01, §p<0.05 between sexes, ¶p<0.001 .
hs-CRP, high-sensitive C reactive protein; LDL, low-density lipid; LV, left ventricular; scMWS, stress-corrected midwall shortening.
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unchanged when total cholesterol, mitral or aortic regurgita-
tion and type of antihypertensive medication were added to the 
covariates. In subsequent Cox analyses, presence of moderate/
severe AVC at baseline was associated with increased all-cause 
mortality only in men and increased hazard of ischaemic cardio-
vascular events only in women (table 3).
DISCUSSION
This post hoc analysis within the large SEAS study is the first to 
demonstrate that AVC in AS scored by echocardiography has 
sex-specific risk factors and that presence of moderate/severe AVC 
at baseline predicts higher rates of major cardiovascular events 
and combined aortic valve replacement and death both in women 
and men. Our sex-specific findings add to previous reports by 
Rosenhek et al.9 10 Furthermore, in this study, an independent asso-
ciation with higher all-cause mortality was found only in men and 
with higher risk of ischaemic cardiovascular events only in women. 
Of note these associations persisted after adjustment in multivar-
iate models for important confounders including age,9 hyperten-
sion,24 AS severity,9 10 aortic compliance, LV structure and systolic 
function,20 hs-CRP and randomised study treatment.
The value of AVC assessment by echocardiography has been 
debated after development of a quantitative method to assess 
valvular macrocalcification by CT.8 The main question about the 
usefulness of echocardiography in assessment of AVC has been 
related to reproducibility. As demonstrated by this study, both 
intraobserver and interobserver reproducibility was excellent. It 
has been demonstrated that AVC by echocardiography, despite 
grossly correlated with CT findings, reveals a higher calcification 
degree than computer tomography, and that the 4-point classifi-
cation system classifies patients with AS in four classes that partly 
overlap in AVC score by CT.8 These differences are, in our view, 
inherent to the physics of ultrasound and X-ray that by their nature 
reveal partially different types of tissue lesion. While CT allows a 
quantitative measurement of macrocalcifications, the echocardio-
graphical AVC scoring assesses semiquantitatively the presence of 
hyperechoic zones that probably also include areas of microcalcifi-
cation and inflammation.6 7 While we acknowledge the diagnostic 
value CT can have in certain groups of patients with AS, as those 
with low-flow, low-grade AS with normal ejection fraction,25 
we believe echocardiography to be the only feasible method to 
be applied in regular follow-up of the majority of patients with 
AS outside specialised heart valve centres. As demonstrated in 
the present analysis, assessment of AVC by echocardiography is 
reliable and of prognostic value both in women and men, inde-
pendent of traditional prognostic markers in AS. Our findings 
add to previous documentation from an international registry 
showing that AVC by CT was associated with increased mortality 
in both sexes.4
Our finding that moderate/severe AVC was less prevalent 
in women than men despite comparable AS severity adds to 
previous studies on AVC by echocardiography9 10 and confirms 
previous observations by CT using the Agatston score.3 Differ-
ences in body surface area, aortic valve weight and aortic 
annulus size documented by previous studies may contribute 
to explain these sex differences.26 The association of AVC 
with lower aortic compliance underlines the systemic arterial 
involvement in degenerative AS.27
Hs-CRP and elevated serum creatine are well-known factors 
associated with atherosclerosis. This study found that higher 
AVC was associated with more severe AS in both sexes, and 
with serum hs-CRP particularly in men. In contrast, the 
Olmsted County study did not find any relation between 
hs-CRP levels and AS severity or the degree of valve calcifica-
tion.28 The Chronic Renal Insufficiency Cohort study reported 
an inversed relation between AVC and estimated glomerular 
filtration rate in patients with non-end-stage chronic kidney 
disease.29 However, when adjusted for cardiovascular risk 
factors such as CRP and homocysteine, the association became 
non-significant. Recently published research demonstrates 
proinflammatory and procoagulation changes in the plasma of 
patients with AS.30 Our study additionally reveals an indepen-
dent association between the systemic inflammatory marker 
hs-CRP and AVC only in men, while no association between 
AVC and serum creatine or estimated glomerular filtration rate 
was found.
Figure 2 Severity of aortic stenosis by the energy loss index assessed 
in women and men and in the two aortic valve calcification (AVC) 
subgroups: no/mild AVC and moderate/severe AVC. p value <0.05 
between women and men in each AVC category.
Table 2 Independent risk factors of moderate/severe AVC in women and men
Women Men
Covariate OR (95% CI) p Value OR (95% CI) p Value
Age (years) 1.02 (1.00 to 1.04) 0.310 1.01 (0.99 to 1.03) 0.176
Aortic compliance (mL/mm Hg) 0.77 (0.66 to 0.91) 0.002 0.85 (0.77 to 0.93) <0.001
ELI (cm²/m²) 0.11 (0.06 to 0.20) <0.001 0.23 (0.15 to 0.34) <0.001
Hs-CRP (mg/dL) 1.26 (0.92 to 1.72) 0.146 1.84 (1.23 to 2.77) 0.003
scMWS (%) 0.99 (0.98 to 1.00) 0.234 0.99 (0.99 to 1.00) 0.116
ELI, energy loss index; hs-CRP, high-sensitive C reactive protein; scMWS, stress-corrected midwall shortening.
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Study limitations
The SEAS study excluded patients with known coronary heart 
disease, heart failure, diabetes mellitus, renal failure, history of 
stroke, peripheral vascular disease and patients with indication for 
lipid-lowering therapy. Thus, projection of results to less selective 
AS patients should be done with caution. AVC is assessed semi-
quantitatively by echocardiography. We acknowledge the value 
of CT in quantitative assessment of valvular macrocalcifications. 
However, as demonstrated, echocardiographic assessment of AVC 
was highly reproducible both for experienced and less experienced 
sonographers and may be more available and feasible in clin-
ical cardiology practice. However, further studies are needed to 
directly compare performance and prognostic value of AVC scored 
by echocardiography and CT.
Figure 3 Kaplan-Meier curves reporting survival free of major cardiovascular events (A), and survival (B) in women (left panels) and men (right 
panels). AVC, aortic valve calcification.
Table 3 The association of baseline moderate/severe aortic valve calcification with study outcomes in women and men
Women Men
n HR (95% CI) p Value n HR (95% CI) p Value
Major cardiovascular events 172 2.50 (1.64 to 3.80) <0.001 270 2.21 (1.54 to 3.17) <0.001
Aortic valve events 162 2.44 (1.58 to 3.76) <0.001 246 2.96 (1.94 to 4.49) <0.001
Ischaemic cardiovascular events 70 1.86 (1.01 to 3.44) 0.047 141 1.51 (0.98 to 2.35) 0.065
All-cause mortality* 47 1.40 (0.70 to 2.79) 0.338 96 1.78 (1.04 to 3.06) 0.036
Aortic valve replacement or death 170 2.19 (1.46 to 3.30) <0.001 279 2.77 (1.90 to 4.05) <0.001
*Model adjusted for age, energy loss index, aortic compliance and left ventricular mass index.
n, number of events.
group.bmj.com on July 15, 2017 - Published by http://heart.bmj.com/Downloaded from 
6 Thomassen HK, et al.  Heart 2017;0:1–6. doi:10.1136/heartjnl-2016-311040
Valvular heart disease
CONCLUSION
In conclusion, in patients with AS and without diabetes mellitus or 
known renal or cardiovascular disease participating in the SEAS 
study, presence of moderate/severe AVC by echocardiography at 
baseline was associated with higher hazard rates of major cardio-
vascular events and combined aortic valve replacement and death 
in both sexes, with higher hazard rates of ischaemic cardiovascular 
events in women and with higher all-cause mortality in men. These 
associations were independent of important confounders including 
older age, hypertension, aortic compliance, AS severity and LV 
structure and function.
Key messages
What is already known on this subject?
Sex-specific risk factors of aortic valve calcification (AVC) scored 
by echocardiography and its prognostic relevance in women and 
men with aortic stenosis (AS) have not been previously reported 
from a large, prospective study.
What might this study add?
This post hoc analysis within the Simvastatin Ezetimibe in Aortic 
Stenosis study is the first to demonstrate sex-specific risk factors 
of AVC scored by echocardiography. Moderate/severe AVC at 
study baseline independently predicted higher rates of major 
cardiovascular events and combined death and aortic valve 
replacement in both sexes, higher hazard rate of ischaemic 
cardiovascular events only in women, and higher all-cause 
mortality only in men.
How might this impact on clinical practice?
Assessment of AVC by echocardiography is highly reproducible 
and of prognostic value in the follow-up of women and men 
with AS, independent of traditional prognostic markers.
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